HDAC8 and acute myeloid leukemia: Moreover, Long et al. demonstrated that histone deacetylase 8 (HDAC8) inhibition reactivates cellular tumor antigen p53 (p53), thereby overcoming TKI resistance in FLT3-ITD+ AML PDX models.